DHFR-IN-4

CAS No. 2820126-49-4

DHFR-IN-4( —— )

Catalog No. M35563 CAS No. 2820126-49-4

DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 523 In Stock
10MG 660 In Stock
25MG 858 In Stock
50MG 1144 In Stock
100MG 1553 In Stock
200MG 2093 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DHFR-IN-4
  • Note
    Research use only, not for human use.
  • Brief Description
    DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.
  • Description
    DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with an IC50 value of 123 nM. DHFR-IN-4 also has inhibitory activity against EGFR and HER2 with IC50s of 246 nM and 357 nM, respectively. DHFR-IN-4 has remarkable broad spectrum cytotoxic potency against cancer cells.
  • In Vitro
    DHFR-IN-4 (compound 42) (0-100 μM; 72 h) shows remarkable broad spectrum cytotoxic potency against HepG2, MCF-7, HCT-116, PC3 and HeLa.Cell Cytotoxicity Assay Cell Line:HepG2, MCF-7, HCT-116, PC3 and HeLa Concentration:0-100 μM Incubation Time:72 h Result:Exhibited antiproliferative activity against HepG2, MCF-7, HCT-116, PC3 and HeLa with IC50s of 9.67±0.7 μM, 8.46±0.7 μM, 13.24±0.9 μM, 11.17±1.0 μM and 6.90±0.5 μM.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DHFR
  • Recptor
    DHFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2820126-49-4
  • Formula Weight
    371.46
  • Molecular Formula
    C18H21N5O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NN)C1=CSC2=NC(=C(C=3C=CC(=CC3)C)N21)CN4CCOCC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sabry MA, et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity. Eur J Med Chem. 2022 Aug 10;241:114661.?
molnova catalog
related products
  • Piritrexim

    Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.

  • Brodimoprim

    Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.

  • WR99210

    WR99210 is effective against the most pyrimethamine-resistant Plasmodium falciparum strains.